Dr Sharman provides an update on an NIH CAR-T trial for relapsed/refractory DBLC

Dr Sharman provides an update on an NIH CAR-T trial for relapsed/refractory DBLC

Many of us will remember the excitement a couple of years back when Dr Carl June of the University of Pennsylvania announced Chimeric Antigen Receptor engineered T Lymphocytes (CAR-T) were successfully used to cure at least one CLL patient.

As Dr Sharman covers in his latest blog, CAR-T research is now being done at a multitude of universities, with one for relapsed DLBCL or multiply recurrent indolent lymphoma being run out of the NIH:


When the CAR-T research was publicised, it was recognised that much more needed to done to provide a more broadly useful treatment, rather than a custom approach per patient. (The trial patients needed to remain on IVIG for life as the treatment kept zapping any new B-Lymphocytes). It's great to know that so many centres are working on extending this alternative approach to finding a cure for some tough leukaemias and lymphomas.

Dr Sharman concludes: "If I had relapsed DLBCL or multiply recurrent indolent lymphoma, I would be on the first plane to NIH for these studies."


(My accompanying picture shows the aptly named 'bottle brush', an attractive native shrub that is sometimes used as a street tree around here. They've been glorious this year after a wet winter.)

3 Replies

  • Hope everyone takes time to read this and look at the video found by clicking on 'amazingly cool video' in the article.

    I had not seen this before, it shows, I guess, there is always hope.


    Wow! to the bottle brush shrub.

  • I noted in the inclusion criteria 'All CLL patients must have previously received Ibrutinib.'

    Makes a bit limiting for us... unless I'm reading it wrong.

  • That's how I read it too Chris, but it doesn't make sense! How many patients will meet their eligibility criteria i.e.

    1) be a non-responder to, or recurred after one or more standard chemotherapy-containing regimens for their malignancy

    2) have previously received Ibrutinib?

    That makes for a very small trial!


You may also like...